Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Monte Rosa Therapeutics
Biotech
Trio of biotechs toss programs to discard pile
Adaptimmune Therapeutics, Monte Rosa Therapeutics and Intellia Therapeutics are all throwing programs to the discard pile.
Gabrielle Masson
Nov 9, 2023 11:23am
Roche pays $50M to Monte Rosa in latest molecular glue deal
Oct 17, 2023 8:25am
Monte Rosa sticks its IPO, landing $222M for 'molecular glues'
Jun 24, 2021 10:30am
BioTheryX skips the SPAC fervor in favor of eventual IPO
May 21, 2021 10:50am
Monte Rosa snags $95M to speed lead 'molecular glue' into clinic
Mar 12, 2021 10:22am
Versant's Monte Rosa banks $96M for 'molecular glue' pipeline
Sep 24, 2020 7:00am